BioSavita
BioSavita is a biotechnology company specializing in accelerated biologics development using genetically engineered yeast strains and proprietary platform technology. Their mission is to provide cost-effective and rapid production of biologics, vaccines, and proteins through innovative yeast-based platforms, addressing multi-billion dollar growth market opportunities.
Industries
Nr. of Employees
small (1-50)
BioSavita
Life Science & Innovation Corridor, 46701 Commerce Center Drive, Plymouth, MI 48170
Products
Yeast‑based biologics production platform (glycoengineered strains + multicopy vectors)
An integrated platform comprising glycoengineered S. cerevisiae strains and plug‑and‑play multicopy expression vectors intended to enable accelerated, cost‑effective production of recombinant proteins, antibodies, and VLP vaccines in microbial fermentation systems.
Yeast‑based biologics production platform (glycoengineered strains + multicopy vectors)
An integrated platform comprising glycoengineered S. cerevisiae strains and plug‑and‑play multicopy expression vectors intended to enable accelerated, cost‑effective production of recombinant proteins, antibodies, and VLP vaccines in microbial fermentation systems.
Services
Partnerships and licensing arrangements to apply glycoengineered yeast strains and multicopy expression systems for development and production of recombinant proteins and vaccines.
Development services for expression, secretion, and analytical characterization of recombinant proteins, antibodies, and VLPs using engineered yeast platforms and associated process optimization.
Partnerships and licensing arrangements to apply glycoengineered yeast strains and multicopy expression systems for development and production of recombinant proteins and vaccines.
Development services for expression, secretion, and analytical characterization of recombinant proteins, antibodies, and VLPs using engineered yeast platforms and associated process optimization.
Expertise Areas
- Yeast‑based biologics production
- Glycoengineering of protein therapeutics
- Vaccine development using microbial platforms
- Antibody discovery and engineering
Key Technologies
- Glycoengineering (N‑glycan manipulation)
- Multicopy yeast expression vectors
- Yeast display for antibody discovery
- Virus‑like particle (VLP) production